INmune Bio (NASDAQ:INMB) Trading 1.7% Higher – What’s Next?

Shares of INmune Bio, Inc. (NASDAQ:INMB) were up 1.7% during mid-day trading on Tuesday . The company traded as high as $4.93 and last traded at $4.88. Approximately 131,907 shares changed hands during trading, a decline of 20% from the average daily volume of 165,580 shares. The stock had previously closed at $4.80.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on INMB shares. Alliance Global Partners started coverage on INmune Bio in a research report on Monday, October 21st. They set a “buy” rating and a $20.00 price target on the stock. Raymond James started coverage on INmune Bio in a research report on Friday, September 27th. They set an “outperform” rating and a $18.00 price target on the stock. Finally, Scotiabank started coverage on INmune Bio in a research report on Thursday, August 22nd. They issued a “sector outperform” rating and a $22.00 target price on the stock.

INmune Bio Trading Up 0.2 %

The firm has a 50-day moving average of $5.35 and a 200-day moving average of $7.13. The stock has a market capitalization of $108.42 million, a price-to-earnings ratio of -2.24 and a beta of 1.85.

INmune Bio (NASDAQ:INMB) last announced its quarterly earnings results on Thursday, October 31st. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.11). INmune Bio had a negative return on equity of 117.48% and a negative net margin of 26,333.59%. During the same period last year, the company earned ($0.48) EPS. On average, equities research analysts anticipate that INmune Bio, Inc. will post -2.24 EPS for the current year.

Insider Transactions at INmune Bio

In related news, CEO Raymond Joseph Tesi purchased 15,380 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The shares were purchased at an average cost of $6.38 per share, with a total value of $98,124.40. Following the purchase, the chief executive officer now owns 1,554,106 shares of the company’s stock, valued at $9,915,196.28. This represents a 1.00 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO David J. Moss purchased 10,000 shares of the firm’s stock in a transaction that occurred on Monday, September 30th. The stock was bought at an average cost of $5.29 per share, for a total transaction of $52,900.00. Following the completion of the purchase, the chief financial officer now directly owns 1,285,869 shares in the company, valued at $6,802,247.01. This represents a 0.78 % increase in their position. The disclosure for this purchase can be found here. Insiders have bought a total of 33,070 shares of company stock valued at $200,087 in the last ninety days. 35.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Financial Advocates Investment Management lifted its stake in INmune Bio by 17.4% in the 3rd quarter. Financial Advocates Investment Management now owns 13,500 shares of the company’s stock valued at $73,000 after buying an additional 2,000 shares in the last quarter. Jane Street Group LLC purchased a new position in INmune Bio in the 3rd quarter worth approximately $79,000. Sanctuary Advisors LLC purchased a new position in INmune Bio in the 3rd quarter worth approximately $113,000. Rhumbline Advisers purchased a new position in INmune Bio in the 2nd quarter worth approximately $121,000. Finally, Barclays PLC lifted its stake in INmune Bio by 601.9% in the 3rd quarter. Barclays PLC now owns 29,044 shares of the company’s stock worth $157,000 after purchasing an additional 24,906 shares in the last quarter. 12.72% of the stock is owned by hedge funds and other institutional investors.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.